{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:20:58Z","timestamp":1758806458783,"version":"3.44.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1053\/j.seminoncol.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:55:43Z","timestamp":1674849343000},"page":"429-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A narrative review of the principal glucocorticoids employed in cancer"],"prefix":"10.1053","volume":"49","author":[{"given":"Nerina","family":"Denaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Carlo","family":"Merlano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josie","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Farci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9230-9288","authenticated-orcid":false,"given":"Chiara","family":"Tommasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Solinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2023.01.004_bib0001","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams","year":"2018","journal-title":"Respir Care"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0002","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.annemergmed.2015.03.003","article-title":"Emergency department corticosteroid use for allergy or anaphylaxis is not associated with decreased relapses","volume":"66","author":"Grunau","year":"2015","journal-title":"Ann Emerg Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0003","article-title":"Corticosteroids for treating sepsis in children and adults","volume":"12","author":"Annane","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cytogfr.2020.06.012","article-title":"A critical evaluation of glucocorticoids in the management of severe COVID-19","volume":"54","author":"Solinas","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00134-021-06394-2","article-title":"Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis","volume":"47","author":"Chaudhuri","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015237","article-title":"Systemic glucocorticoid use in Denmark: a population-based prevalence study","volume":"7","author":"Laugesen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/026921600669298725","article-title":"The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?","volume":"14","author":"Laval","year":"2000","journal-title":"Palliat Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0008","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jneuroim.2012.06.001","article-title":"Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours","volume":"250","author":"Lewis","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0009","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.1988.6.3.543","article-title":"Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review","volume":"6","author":"Weissman","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0010","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0011","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1186\/s12885-020-07142-3","article-title":"Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody","volume":"20","author":"Matsuoka","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0012","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.mce.2010.07.013","article-title":"Origin and diversification of steroids: co-evolution of enzymes and nuclear receptors","volume":"334","author":"Baker","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.rdc.2015.08.004","article-title":"Infection risk and safety of corticosteroid use","volume":"42","author":"Youssef","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0014","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.wneu.2016.01.033","article-title":"Association of steroid use with deep venous thrombosis and pulmonary embolism in neurosurgical patients: a national database analysis","volume":"89","author":"Lieber","year":"2016","journal-title":"World Neurosurg"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.steroids.2009.09.002","article-title":"The human glucocorticoid receptor: molecular basis of biologic function","volume":"75","author":"Nicolaides","year":"2010","journal-title":"Steroids"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0016","doi-asserted-by":"crossref","first-page":"S280","DOI":"10.21037\/tcr.2017.03.52","article-title":"IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm","volume":"6","author":"White","year":"2017","journal-title":"Transl Cancer Res"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0017","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1038\/s41467-020-17339-6","article-title":"Tumors induce de novo steroid biosynthesis in T cells to evade immunity","volume":"11","author":"Mahata","year":"2020","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0018","doi-asserted-by":"crossref","first-page":"9573","DOI":"10.1073\/pnas.160099797","article-title":"Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids","volume":"97","author":"Bianchi","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0019","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4049\/jimmunol.132.1.266","article-title":"Inhibition of T cell-mediated cytotoxicity by anti-inflammatory steroids","volume":"132","author":"Schleimer","year":"1984","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0020","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s00262-020-02555-2","article-title":"The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade","volume":"69","author":"Okoye","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0021","doi-asserted-by":"crossref","first-page":"E1213","DOI":"10.3390\/cancers11081213","article-title":"LAG3: the biological processes that motivate targeting this immune checkpoint molecule in human cancer","volume":"11","author":"Solinas","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0022","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13075-015-0564-y","article-title":"Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab","volume":"17","author":"de Jong","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143689","article-title":"Regulatory T cell responses to high-dose methylprednisolone in active systemic lupus erythematosus","volume":"10","author":"Mathian","year":"2015","journal-title":"PLoS One"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0024","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.4049\/jimmunol.158.12.5589","article-title":"Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes","volume":"158","author":"Blotta","year":"1997","journal-title":"J Immunol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0025","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/ijc.32080","article-title":"Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs","volume":"145","author":"Draghi","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0026","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.21037\/tlcr-20-635","article-title":"Exploring the immune-checkpoint inhibitors\u2019 efficacy\/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease","volume":"10","author":"Passiglia","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0027","doi-asserted-by":"crossref","first-page":"E2827","DOI":"10.3390\/cancers12102827","article-title":"Impact of intercurrent introduction of steroids on clinical outcomes in advanced Non-Small-Cell Lung Cancer (NSCLC) patients under Immune-Checkpoint Inhibitors (ICI)","volume":"12","author":"De Giglio","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1500108","article-title":"Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system","volume":"7","author":"Maxwell","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.837577","article-title":"Influence of dexamethasone premedication on acute lung toxicity in lung SBRT","volume":"12","author":"Alite","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0030","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.3390\/cancers14051296","article-title":"Is timing of steroid exposure prior to immune checkpoint inhibitor initiation associated with treatment outcomes in melanoma? A population-based study","volume":"14","author":"Nikita","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0031","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0032","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.jtho.2018.06.004","article-title":"Early use of systemic corticosteroids in patients with advanced NSCLC treated with Nivolumab","volume":"13","author":"Scott","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0033","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000457","article-title":"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors","volume":"4","author":"Fuc\u00e0","year":"2019","journal-title":"ESMO Open"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0034","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1515\/jtim-2016-0011","article-title":"A little help from steroids in oncology","volume":"4","author":"Lossignol","year":"2016","journal-title":"J Transl Int Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0036","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","article-title":"The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights","volume":"335","author":"Coutinho","year":"2011","journal-title":"Mol Cell Endocrinol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0037","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1526-4637.2010.00840.x","article-title":"Cancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners","volume":"11","author":"Raphael","year":"2010","journal-title":"Pain Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0038","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11916-012-0273-z","article-title":"The role of corticosteroids in the treatment of pain in cancer patients","volume":"16","author":"Leppert","year":"2012","journal-title":"Curr Pain Headache Rep"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0039","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainresrev.2007.06.006","article-title":"Listening\u201d and \u201ctalking\u201d to neurons: implications of immune activation for pain control and increasing the efficacy of opioids","volume":"56","author":"Watkins","year":"2007","journal-title":"Brain Res Rev"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/ecp.11.1","article-title":"Corticosteroids in brain cancer patients: benefits and pitfalls","volume":"4","author":"Dietrich","year":"2011","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0041","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/pgmj.59.697.702","article-title":"Corticosteroids in terminal cancer\u2013a prospective analysis of current practice","volume":"59","author":"Hanks","year":"1983","journal-title":"Postgrad Med J"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0042","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrclinonc.2014.127","article-title":"Cancer-related fatigue\u2013mechanisms, risk factors, and treatments","volume":"11","author":"Bower","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0043","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/cncr.33975","article-title":"Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer","volume":"128","author":"Ryan","year":"2022","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0044","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1002\/cncr.10891","article-title":"Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: daily self-report and objective behavior","volume":"95","author":"Servaes","year":"2002","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2023.01.004_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1634\/theoncologist.12-S1-22","article-title":"Mechanisms of cancer-related fatigue","volume":"12","author":"Ryan","year":"2007","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0046","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2012.44.4661","article-title":"Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer","volume":"31","author":"Yennurajalingam","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0047","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1200\/JCO.2013.54.3926","article-title":"Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled, double-blind trial","volume":"32","author":"Paulsen","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0048","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.biocel.2013.05.036","article-title":"Glucocorticoid-induced skeletal muscle atrophy","volume":"45","author":"Schakman","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0049","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/026921601673324846","article-title":"A prospective survey of the use of dexamethasone on a palliative care unit","volume":"15","author":"Hardy","year":"2001","journal-title":"Palliat Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0050","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.44.4.675","article-title":"Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day","volume":"44","author":"Vecht","year":"1994","journal-title":"Neurology"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0051","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.annemergmed.2006.01.018","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2013second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"47","author":"Sampson","year":"2006","journal-title":"Ann Emerg Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0052","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1200\/JCO.21.01200","article-title":"Do steroids matter? A retrospective review of premedication for taxane chemotherapy and hypersensitivity reactions","volume":"39","author":"Lansinger","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0053","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2013.10.008","article-title":"The cellular mechanisms of the antiemetic action of dexamethasone and related glucocorticoids against vomiting","volume":"722","author":"Chu","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0054","first-page":"277","article-title":"2016 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy","volume":"25","author":"Herrstedt","year":"2017","journal-title":"Supp Care Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056781","article-title":"Preventive effects of betamethasone valerate ointment for radiation-induced severe oral mucositis in patients with oral or oropharyngeal cancer: protocol for a multicentre, phase II, randomised controlled trial (Bet-ROM study)","volume":"12","author":"Soutome","year":"2022","journal-title":"BMJ Open"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0056","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","article-title":"Mechanisms, management and prevention of pemetrexed-related toxicity","volume":"44","author":"de Rouw","year":"2021","journal-title":"Drug Saf"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0098","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti...CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0057","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0058","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0059","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0060","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0000000000000635","article-title":"Emergency management of immune-related toxicity","volume":"32","author":"Cooksley","year":"2020","journal-title":"Curr Opin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0061","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/gut.19.12.1131","article-title":"Oral prednisone for chronic active liver disease: dose responses and bioavailability studies","volume":"19","author":"Uribe","year":"1978","journal-title":"Gut"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0062","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/j.seminoncol.2018.09.002","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"45","author":"Solinas","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0063","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-17-0009","article-title":"Mechanisms in endocrinology: hypophysitis: diagnosis and treatment","volume":"179","author":"Joshi","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0064","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0065","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0066","first-page":"386","article-title":"The use of corticosteroids in home palliative care","volume":"9","author":"Mercadante","year":"2001","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0067","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jpainsymman.2013.10.018","article-title":"Subcutaneous administration of drugs in palliative care: results of a systematic observational study","volume":"48","author":"Bartz","year":"2014","journal-title":"J Pain Symptom Manag"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0068","unstructured":"SC-Guidelines-Palliative-care-R.pdf n.d."},{"year":"2018","series-title":"L'art de soigner en soins palliatifs\u202f: Perspectives infirmi\u00e8res","author":"Foucault","key":"10.1053\/j.seminoncol.2023.01.004_bib0069"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0070","first-page":"1627","article-title":"Pain and palliative care center. similarities, differences, a necessary collaboration","volume":"26","author":"Laval","year":"1997","journal-title":"Presse Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0071","first-page":"65","article-title":"Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care","volume":"10","author":"Negro","year":"2002","journal-title":"Support Care Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0072","first-page":"8","article-title":"Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol","volume":"11","author":"Gupta","year":"2013","journal-title":"J Support Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0073","article-title":"Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery)","volume":"7","author":"Vayne-Bossert","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0074","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jpainsymman.2009.08.010","article-title":"Palliative medicine study group of the multinational association of supportive care in cancer. A systematic review of the treatment of nausea and\/or vomiting in cancer unrelated to chemotherapy or radiation","volume":"39","author":"Davis","year":"2010","journal-title":"J Pain Symptom Manage"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0075","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpainsymman.2015.10.023","article-title":"Dexamethasone for dyspnea in cancer patients: a pilot double-blind, randomized, controlled trial","volume":"52","author":"Hui","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0076","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/2192568217699189","article-title":"Corticosteroid treatment for metastatic spinal cord compression: a review","volume":"7","author":"Skeoch","year":"2017","journal-title":"Global Spine J"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0077","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/BSD.0000000000000528","article-title":"Metastatic spinal cord compression and steroid treatment: a systematic review","volume":"30","author":"Kumar","year":"2017","journal-title":"Clin Spine Surg"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0078","doi-asserted-by":"crossref","first-page":"586","DOI":"10.14423\/SMJ.0000000000000700","article-title":"Management of metastatic spinal cord compression","volume":"110","author":"Sodji","year":"2017","journal-title":"South Med J"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0079","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/bmjspcare-2015-001037","article-title":"Pharmacovigilance in hospice\/palliative care: the net immediate and short-term effects of dexamethasone for anorexia","volume":"6","author":"Hatano","year":"2016","journal-title":"BMJ Support Palliat Care"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0080","article-title":"Cancer cachexia in adult patients: ESMO clinical practice guidelines","volume":"6","author":"Loblaw","year":"2021","journal-title":"ESMO Open"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0081","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ijrobp.2012.01.014","article-title":"A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression","volume":"84","author":"Loblaw","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0082","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0083","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0084","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJMc1505197","article-title":"Anti-PD-1-related pneumonitis during cancer immunotherapy","volume":"373","author":"Nishino","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0085","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0086","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.rdc.2016.09.007","article-title":"Immune-related adverse effects of cancer immunotherapy- implications for rheumatology","volume":"43","author":"Cappelli","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0087","doi-asserted-by":"crossref","first-page":"355","DOI":"10.31138\/mjr.31.3.355","article-title":"Arthritis and myositis in a patient treated with programmed cell death-1 (PD-1) inhibitor pembrolizumab for lung cancer","volume":"31","author":"Pagkopoulou","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0088","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune checkpoint inhibitors and immune-related adverse renal events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0089","first-page":"49","article-title":"Management of acute pancreatitis associated with checkpoint inhibitors","volume":"11","author":"Rogers","year":"2020","journal-title":"J Adv Pract Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0090","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1634\/theoncologist.2019-0250","article-title":"Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. food and drug administration adverse event reporting system","volume":"24","author":"Raschi","year":"2019","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0091","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/OP.20.00002","article-title":"Immune checkpoint inhibitor-mediated diarrhea and colitis: a clinical review","volume":"16","author":"Gong","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0092","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/17425255.2019.1574744","article-title":"Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies","volume":"15","author":"Jennings","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0093","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/annonc\/mdx126","article-title":"Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient","volume":"28","author":"Pellegrino","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0094","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/1744666X.2020.1804362","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management","volume":"16","author":"Williams","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0095","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1634\/theoncologist.2018-0359","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated neurologic toxicity: illustrative case and review of the literature","volume":"24","author":"Reynolds","year":"2019","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0096","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","article-title":"Immune checkpoint immunotherapy for non-small cell lung cancer: benefits and pulmonary toxicities","volume":"154","author":"Suresh","year":"2018","journal-title":"Chest"},{"key":"10.1053\/j.seminoncol.2023.01.004_bib0097","article-title":"Causes of pruritus in patients treated with immune checkpoint inhibitors for melanomas or skin carcinomas","volume":"8","author":"Salinas","year":"2021","journal-title":"Front Med (Lausanne)"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775423000040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775423000040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:57:38Z","timestamp":1758805058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775423000040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0093775423000040"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2023.01.004","relation":{},"ISSN":["0093-7754"],"issn-type":[{"type":"print","value":"0093-7754"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A narrative review of the principal glucocorticoids employed in cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}